90 Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis

作者：Helena Lanzafame, Ilektra Antonia Mavroeidi, Kim Magaly Pabst, Pedro Fragoso Costa, Martin Schuler, Sebastian Bauer, Jens Kurth, Martin Heuschkel, Jens Thomas Siveke, Ken Herrmann, Karina Kostbade, David Kersting, Stephan Leyser, Stefan Fröhling, Christoph E. Heilig, Rainer Hamacher, Wolfgang P. Fendler · 发表于：Journal of Nuclear Medicine · 年份：2026 · DOI：10.2967/jnumed.125.271135 · 被引用次数：5 · 研究领域：Peptidase Inhibition and Analysis、Connective tissue disorders research、Orthopedic Infections and Treatments

Fibroblast activation protein (FAP) is highly expressed in many cancers, especially sarcomas, and represents a promising theranostic target. We present an updated retrospective analysis of 90Y-FAP inhibitor (FAPI)–46 treatment in patients with sarcoma or other solid tumors. Methods: We performed monocentric analysis of patients with progressive sarcoma or metastatic cancer who were eligible for 90Y-FAPI-46 therapy after approved treatments had been exhausted and who showed high FAP expression (SUVmax, ≥10 in over 50% of lesions on 68Ga-FAPI-46 PET). After therapy, 90Y-FAPI-46 scintigraphy confirmed distribution and uptake, and serial 90Y-FAPI-46 PET/CT scans measured absorbed doses. Adverse events were graded by Common Terminology Criteria for Adverse Events version 5.0. Tumor responses were evaluated using RECIST and PERCIST. Results: Thirty patients—23 (77%) with sarcoma, 3 (10%) with pancreatic cancer, 1 (3%) with prostate cancer, 1 (3%) with gastric cancer, 1 (3%) with nonmelanoma skin cancer, and 1 (3%) with cholangiocarcinoma—received a total of 77 cycles of 90Y-FAPI-46 radiopharmaceutical therapy between June 2020 and December 2023 and were followed until death or the last follow-up (April 2024). The median interval between cycles was 5 mo (interquartile range [IQR], 4 mo). Of the 30 patients, 11 (37%) received 4 or more cycles. A median of 3.7 GBq (IQR, 3.7–3.8 GBq) was administered during the first cycle, and a median of 7.4 GBq (IQR, 7.2–7.4 GBq) was administered fo...